Public perceptions and willingness-to-pay regarding over-the-counter (OTC) naloxone: A national cross-sectional survey informed by the Theory of Planned Behavior Authors: Autumn Randles, Emma Tidmore, Kathlyn Smith, Melissa Sanders, Asia White, Allison Given, Amelia Unione Contreras, Alex Rodriguez-Ramos, Cameron Carter, Anne Taylor, Nicholas McCormick, Brandy Davis, Lindsey Hohmann Published: 2026 ABSTRACT BackgroundLittle is known regarding the U.S. general public's beliefs and willingness to purchase over-the-counter (OTC) naloxone. Therefore, the purpose of this study was to better understand the U.S. public's knowledge, perceptions, and willingness-to-pay regarding OTC naloxone nasal spray, and differences across sociodemographic characteristics.MethodsAdults residing in the US were recruited to participate in an online, anonymous cross-sectional survey using Amazon's Mechanical Turk (MTurk) in September 2023. The survey instrument was developed by the investigators, guided by the Theory of Planned Behavior (TPB). Outcomes included: 1) awareness and knowledge; 2) willingness-to-pay (WTP); 3) community pharmacy preferences; 4) perceived access in community pharmacies; 5) perceived acquisition barriers; 6) utilization comfort; and 7) TPB constructs including general attitudes, subjective norms, perceived behavioral control, and purchase intention. Data was analyzed using descriptive statistics, and Mann-Whitney U tests assessed differences in outcomes across chronic pain history, substance use disorder (SUD) experience, prescription opioid use history, annual household income, sex, race/ethnicity, and rurality.ResultsAmong 299 respondents, awareness was low (31.8%), with mean(SD) WTP of $27.06(25.44). There was higher perceived pharmacy access, comfort, general attitudes, and purchase intentions among those reporting a history of chronic pain. Likewise, those with exposure to SUD reported more positive attitudes and higher purchase intentions. Females perceived more barriers to OTC naloxone access versus males, and WTP was lower among those reporting annual household income <$50,000.ConclusionOverall, WTP for OTC naloxone was lower than average retail prices. Perceptions, intentions, and WTP differed across sociodemographics. Future studies may further investigate these disparities. Background Opioid use and overdoses remain an issue of concern in the United States, necessitating additional steps to combat the opioid epidemic. After a significant rise in opioid-related overdose fatalities from 49,860 to 81,806 between 2019 and 2022, a decline to 79,358 was seen in 2023.1 This was driven by decreases of 33.3% for heroin, 17.1% for natural and semisynthetic opioids, and 2.2% for synthetic (including fentanyl) overdose death rates from 2022 to 2023.2 However, despite this decline, opioid-involved overdoses contribute to 217 deaths per day in the U.S.3 Indeed, 25.5% of respondents to the National Survey on Drug Use and Health reported using illicit substances in the past year in 2024, and 4.8 million reported having an opioid use disorder.4 Further, socioeconomic factors including lack of health insurance, incarceration, and housing instability can increase the risk of fatal overdose, with individuals in urban areas more likely to experience a fatal overdose when compared to individuals in rural areas.5 Sex and race disparities also persist, with opioid-related overdose deaths higher among males compared to females,1 and Native Hawaiian or Other Pacific Islander people experiencing the largest increase (39.4%) in drug overdose mortalities from 2022 to 2023 compared to other races.2 Therefore, accessible methods for opioid harm reduction among all members of the lay public are critical. Take-home naloxone is one solution to prevent opioid overdose mortality. If administered in time, naloxone can effectively reverse opioid overdose. In 2023, 76% (79,358/105,007) of drug overdoses were from opioids,2, 3. and one in three of these opioid overdoses typically occur in the presence of another person, allowing for potential naloxone administration by a bystander.6 A San Francisco study showed that, when available, naloxone reversed 89% of overdose events.7 In order to increase access to naloxone, legislation has been passed in all 50 U.S. states to allow individuals to obtain prescription forms of naloxone (including intramuscular injection and intranasal forms) in a community pharmacy without a physician visit.8 This legislation varies by state, but often takes the form of a statewide standing order allowing pharmacists to dispense naloxone under the authority of the state health officer, or via pharmacists' prescriptive authority in some states.8 As a result of these policies, in 2023 there were 0.6 naloxone prescriptions dispensed from community pharmacies for every 100 persons in the U.S., totaling 2.1 million prescriptions annually.9 The highest rates of naloxone prescriptions dispensed in 2023 occurred in Arkansas, New Mexico, Rhode Island, Wyoming, and Kentucky.9 Implementation of these pharmacy-based naloxone protocols has led to reductions in opioid-related overdose fatalities, with an annual rate decline of 0.84 among municipalities in Massachusetts that implemented pharmacy naloxone standing orders compared to those that did not.10 However, despite these advances, naloxone access via pharmacy standing order remains limited by variability in state policy implementation, pharmacy opt-out, lack of access to transportation, affordability, shortages or lack of stock, stigma, and lack of education about the product.8., 11., 12, 13 Indeed, nationwide community pharmacy-based prescription naloxone availability can range from 30 to 95% depending on the geographic location,12 with one study showing that 41% of community pharmacies in Mississippi were unwilling to dispense naloxone using the standing order.12 Mississippi is a state where over 50% of counties do not have adequate access to primary care physicians, demonstrating the need for access in community pharmacies.14 Additionally, for those who have prescription insurance, copays for naloxone dispensed via standing order vary widely depending on the plan and the formulation to be dispensed.11 Patients may also face delayed access due to the need for prior authorizations and insurance fill limits.11 The average out-of-pocket cost of prescription naloxone for those without insurance in 2022 was approximately $70.15 For those with private or commercial insurance this was approximately $12, while Medicaid and Medicare subscribers saw an average cost of $0.89 and $13.50, respectively.15 Even for those with lower copays, there is still concern for limited income and high costs of other prescriptions that may limit their ability to afford another medication.15 Thus, strategies to increase lay access to naloxone beyond the standing order model remain crucial. In parallel with pharmacy-based standing orders, in efforts to further increase access, many states and counties have expanded availability of no-cost or reduced-cost naloxone. For example, some states such as Oklahoma have naloxone available in vending machines along highways, in casinos, and in fire stations.16 Many health departments and community programs also offer free or reduced-price naloxone.16 While these programs play a critical role in overdose prevention, particularly for individuals at highest risk, they may be geographically limited, episodic, or unfamiliar to members of the general public who do not perceive themselves or their immediate networks to be at risk for overdose.13 As a result, community pharmacies remain an important and accessible point of naloxone distribution for the broader public, including individuals prescribed opioids for legitimate medical use and their friends or family members, as well as those living in medical deserts with few options for care. Indeed, community pharmacies are widely distributed, operate during extended hours, and are frequently accessed for routine healthcare needs, positioning them as a key setting for continued naloxone access.17 In response to persistent access barriers, in March 2023 the U.S. Food and Drug Administration (FDA) granted over-the-counter (OTC) status to naloxone nasal spray, and it became available for sale in September of that year.18 Unlike standing-order models, OTC naloxone does not require pharmacy participation in state protocols. However, pharmacy decisions regarding OTC product stocking, placement, pricing, and promotion may continue to influence real-world access, with recent literature showing variability in these factors across pharmacies.19, 20, 21 In particular, while OTC naloxone is increasingly available at community pharmacies, big box stores, and online, the average cost of approximately $45.00 for two intranasal (IN) sprays22 raises concerns about affordability.20, 21 Despite these concerns, little is known about the U.S. general public's awareness of and willingness to purchase OTC naloxone, information that is essential for informing pharmacy practice, public health messaging, and pricing and policy strategies aimed at maximizing the population-level impact of OTC naloxone availability. Accordingly, the purpose of this study was to better understand the U.S. public's knowledge, perceptions, and willingness-to-pay regarding OTC naloxone nasal spray, as well as differences across sociodemographic characteristics, with the goal of improving community pharmacy naloxone services. Methods Study design, participants, and recruitment This study employed a cross-sectional design and was conducted in September 2023. Participants aged 18 years or older residing in the U.S. were recruited to participate in a survey using Amazon's Mechanical Turk (MTurk), an online crowdsourcing platform with precedents for use in the healthcare field.17, 23, 24, 25 MTurk “pushes” electronic notifications to eligible individuals who have signed up to complete projects via the platform; participation in any specific project is voluntary and at the discretion of the individual. To ensure robust and high-quality survey responses, eligibility was restricted to those with MTurk “Master” status, indicating a history of reliable work on the platform.26 Participants were compensated $5 USD for completing the survey. Sample size estimation A power analysis was conducted using G*Power software version 3.1.9.7 (Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany). Based on this analysis, a minimum sample size of 139 was determined to be sufficient to assess predictors of OTC naloxone purchase intentions (the primary outcome measure of interest) with 80% power, assuming a medium effect size of f2 = 0.1527 and probability of a Type I error of α = 0.05. Data collection and measures Data were collected through an anonymous electronic survey distributed via the MTurk platform. The survey instrument was developed by the authors and guided by the Theory of Planned Behavior (TPB),28 with items adapted from prior studies by Slocum et al. (2022)29 and Huang et al. (2022).30 Survey items were pre-tested among members of the corresponding author's department and modified based on feedback prior to distribution, with the final instrument anticipated to take approximately 30 min to complete. Primary outcome measures included: 1) awareness and knowledge of OTC naloxone (4-items); 2) willingness-to-pay (WTP) for OTC naloxone in the community pharmacy setting (4-items); 3) preferences regarding OTC naloxone sales in the community pharmacy setting (10-items); 4) perceived ability to access OTC naloxone in local community pharmacies (10-items); 5) perceived barriers to obtaining OTC naloxone (8-items); 6) comfort utilizing OTC naloxone (12-items); 7) TPB constructs including general attitudes about OTC naloxone (13-items), subjective norms (operationalized as negative social pressure; 9-items), perceived behavioral control (operationalized as confidence in ability to obtain OTC naloxone; 12-items), and intention to obtain OTC naloxone (7-items). Awareness and knowledge were measured via multiple-choice questions, while willingness-to-pay was assessed using a combination of open-ended (1-item) and multiple-choice (3-items) questions. Community pharmacy preferences were measured via a multiple-choice index rated from 1 = strongly disagree to 5 = strongly agree. Perceived pharmacy access, perceived barriers, comfort, and TPB constructs were measured via 5-point Likert-type scales (1 = strongly disagree to 5 = strongly agree). Secondarily, history of naloxone utilization and access were assessed via a mix of multiple-choice (5-items) and open-ended (1-item) questions, including naloxone purchase history (Yes/No), frequency of obtaining naloxone, and source of naloxone. History of chronic pain (Yes/No), experience with opioid or substance use disorder (Yes/No), and history of prescription opioid use (Yes/No) were also measured via three dichotomous multiple-choice questions. Demographics were measured via self-report. The full survey instrument is available in Supplemental File 1. Data analysis Descriptive statistics were conducted to characterize participant demographics and outcome measures, including frequencies, percentages, means, and standard deviations. TPB, perceived barriers, comfort, and perceived pharmacy access items were summed and averaged to create overall scale scores, and Cronbach's alpha was calculated to assess the internal consistency of survey scales. Items were reverse coded as necessary prior to calculation of scale scores, such that higher scale scores indicated more of a construct (e.g., higher intentions, more positive attitudes, more social pressure, more barriers, higher comfort). Differences in average scale scores and average WTP across history of chronic pain (yes/no), experience with substance use disorder (yes/no), history of prescription opioid use (yes/no), annual household income (<$50,000 versus ≥$50,000 per year), sex (male versus female), race/ethnicity (White versus Asian, Black or African American, Hispanic or Latino/a/x, Multiracial, Native American or Alaska Native, Native Hawaiian or Other Pacific Islander, or Other), and rurality (urban versus rural geographic location) were assessed using two-sided Mann-Whitney U tests with α = 0.05. Non-parametric Mann-Whitney U tests were conducted due to the non-normal distribution of the survey scale data (Shapiro-Wilks tests p < 0.05) and right-skewed WTP responses (skewness = 3.23), as these tests are less sensitive to non-normality and extreme values compared to parametric alternatives. Geographic location was categorized as urban or rural based on participant zip codes according to the Rural Urban Commuting Area (RUCA) codes (urban = RUCA 1–3, rural = RUCA 4–10).31 Rank-biserial correlation coefficients (rrb) were used as a measure of effect size as recommended by Pautz et al. for Mann-Whitney U tests,32 and interpreted based on Cohen's guidelines (r of 0.1 = small, 0.3 = medium, 0.5 = large)32, 33 Additionally, predictors of intention to purchase OTC naloxone were assessed via multiple linear regression. Utilizing the overall intention mean scale score as the dependent variable, two regression models were analyzed, including an unadjusted (Model 1) and adjusted (Model 2) model. Model 1 included general attitudes, subjective norms, perceived behavioral control, perceived barriers, comfort, and perceived pharmacy access mean scale scores as predictor variables. Model 2 included the aforementioned predictors, while also controlling for covariates of naloxone purchase history (Yes/No), sex, age, race/ethnicity, education level, annual household income, history of chronic pain (Yes/No), experience with opioid or substance use disorder (Yes/No), and history of prescription opioid use (Yes/No). Missing data due to item non-response was excluded from analyses. Data was analyzed using SPSS Statistics software version 29 (IBM Corp., Armonk, New York, USA). Study findings are reported according to the “Strengthening the Reporting of Observational Studies in Epidemiology” (STROBE) guidelines for cross-sectional studies.34 Ethics approval This study was reviewed and approved by corresponding author's Institutional Review Board to ensure adherence to ethical guidelines for research involving human subjects (Protocol #23–412 EX 2308). Participation was voluntary, and informed consent was obtained electronically before survey completion. All responses were collected anonymously to protect participant confidentiality. Results There were a total of 299 survey responses. A majority of the respondents were White (77.2%) and male (52.5%), with a mean age of 44.8 years (Table 1). Respondents mainly came from urban households (83.4%) with an annual income of $25,000–$49,999 (30.3%) or $50,000–$74,999 (23.8%) and held a bachelor's-level college degree (40.1%). Furthermore, 30.1% of respondents were diagnosed with chronic pain, 45.2% had been personally or professionally affected by opioid use disorder or substance misuse, and 34.8% had a history of prescription opioid use.Table 1Participant Characteristics (N = 299).Characteristicsn (%) aSexMale156 (52.5)Female137 (46.1)Race and EthnicityAmerican Indian or Alaska Native3 (1.0)Asian18 (6.0)Black or African American25 (8.4)Native Hawaiian or Other Pacific Islander1 (0.3)Hispanic or Latino/a/x14 (4.7)White230 (77.2)Multiracial6 (2.0)Other1 (0.3)Annual Household IncomeLess than $25,00041 (13.9)$25,000–$49,99989 (30.3)$50,000–$74,99970 (23.8)$75,000–$99,99953 (18.0)$100,000–$124,99913 (4.4)$125,000–$149,99914 (4.8)$150,000 or more14 (4.8)Highest Level Education CompletedHigh school or GED41 (13.7)Some college, no degree50 (16.7)Trade/technical/vocational training12 (4.0)Associate's degree46 (15.4)Bachelor's degree120 (40.1)Master's degree23 (7.7)Professional degree (e.g., MD, PharmD, JD)5 (1.7)Doctorate degree (e.g., PhD, EdD)2 (0.7)RuralityUrban247 (83.4)Rural49 (16.6)Are you currently, or have you ever in the past, been diagnosed with chronic pain?Yes88 (30.1)No204 (69.9)Have you or someone you have known been personally or professionally affected by opioid use disorder (OUD) or substance misuse?Yes132 (45.2)No160 (54.8)Are you currently using prescription opioid medications or have you been prescribed opioid medications in the past for the treatment of pain or for post-surgery management in the outpatient setting (not in a hospital)? Prescription opioid medications may include morphine, hydrocodone, oxycodone, Norco®, Percocet®, or others.Yes102 (34.8)No191 (65.2)Have you ever purchased or otherwise obtained naloxone?Yes24 (8.0)No275 (92.0)From where did you obtain naloxone? Please check all that apply. bSupport group1 (4.17)Pharmacy7 (29.17)Harm reduction program (e.g., public health department, community coalition)10 (41.67)Hospital2 (4.26)Doctor office or clinic2 (4.26)Treatment or recovery center3 (12.50)Friend or family member4 (16.67)Police department0Fire department1 (4.17)Emergency Medical Technician (EMT)1 (4.17)Is naloxone currently available for you, friends, or family members to use in your home?Yes32 (10.7)No267 (89.3)Is everyone in your household aware of where naloxone is located in the home? cYes16 (50.0)No16 (50.0)Does everyone in your household know how to use naloxone? cYes13 (40.6)No19 (59.4)Mean (SD)Median (IQR)Age, years44.80 (10.63)43.00 (37.00–51.00)Approximately how many times have you obtained naloxone? a2.83 (4.01)1.00 (1.00–3.00)Range: 1–20aFrequencies and percentages may differ due to item non-response.bQuestion displayed to those who responded “Yes” to “Have you ever purchased or otherwise obtained naloxone?”cQuestion displayed to those who responded “Yes” to “Is naloxone currently available for you, friends, or family members to use in your home?” Table 1Participant Characteristics (N = 299).Characteristicsn (%) aSexMale156 (52.5)Female137 (46.1)Race and EthnicityAmerican Indian or Alaska Native3 (1.0)Asian18 (6.0)Black or African American25 (8.4)Native Hawaiian or Other Pacific Islander1 (0.3)Hispanic or Latino/a/x14 (4.7)White230 (77.2)Multiracial6 (2.0)Other1 (0.3)Annual Household IncomeLess than $25,00041 (13.9)$25,000–$49,99989 (30.3)$50,000–$74,99970 (23.8)$75,000–$99,99953 (18.0)$100,000–$124,99913 (4.4)$125,000–$149,99914 (4.8)$150,000 or more14 (4.8)Highest Level Education CompletedHigh school or GED41 (13.7)Some college, no degree50 (16.7)Trade/technical/vocational training12 (4.0)Associate's degree46 (15.4)Bachelor's degree120 (40.1)Master's degree23 (7.7)Professional degree (e.g., MD, PharmD, JD)5 (1.7)Doctorate degree (e.g., PhD, EdD)2 (0.7)RuralityUrban247 (83.4)Rural49 (16.6)Are you currently, or have you ever in the past, been diagnosed with chronic pain?Yes88 (30.1)No204 (69.9)Have you or someone you have known been personally or professionally affected by opioid use disorder (OUD) or substance misuse?Yes132 (45.2)No160 (54.8)Are you currently using prescription opioid medications or have you been prescribed opioid medications in the past for the treatment of pain or for post-surgery management in the outpatient setting (not in a hospital)? Prescription opioid medications may include morphine, hydrocodone, oxycodone, Norco®, Percocet®, or others.Yes102 (34.8)No191 (65.2)Have you ever purchased or otherwise obtained naloxone?Yes24 (8.0)No275 (92.0)From where did you obtain naloxone? Please check all that apply. bSupport group1 (4.17)Pharmacy7 (29.17)Harm reduction program (e.g., public health department, community coalition)10 (41.67)Hospital2 (4.26)Doctor office or clinic2 (4.26)Treatment or recovery center3 (12.50)Friend or family member4 (16.67)Police department0Fire department1 (4.17)Emergency Medical Technician (EMT)1 (4.17)Is naloxone currently available for you, friends, or family members to use in your home?Yes32 (10.7)No267 (89.3)Is everyone in your household aware of where naloxone is located in the home? cYes16 (50.0)No16 (50.0)Does everyone in your household know how to use naloxone? cYes13 (40.6)No19 (59.4)Mean (SD)Median (IQR)Age, years44.80 (10.63)43.00 (37.00–51.00)Approximately how many times have you obtained naloxone? a2.83 (4.01)1.00 (1.00–3.00)Range: 1–20aFrequencies and percentages may differ due to item non-response.bQuestion displayed to those who responded “Yes” to “Have you ever purchased or otherwise obtained naloxone?”cQuestion displayed to those who responded “Yes” to “Is naloxone currently available for you, friends, or family members to use in your home?” Participant Characteristics (N = 299). Frequencies and percentages may differ due to item non-response. Question displayed to those who responded “Yes” to “Have you ever purchased or otherwise obtained naloxone?” Question displayed to those who responded “Yes” to “Is naloxone currently available for you, friends, or family members to use in your home?” Additionally, history of naloxone utilization was low, with only 8.0% of respondents having ever purchased or obtained naloxone. Of the individuals that had obtained naloxone, there was a mean (SD) frequency of 2.83 (4.01) naloxone acquisitions per person, and the most common source was through a harm reduction program (41.7%), pharmacy (29.17%), or friend or family member (16.67%). Only 10.7% of respondents reported that naloxone was currently available for themselves, friends, and family members to use in their home. Of these, only 50% indicated that everyone in the household was aware of where naloxone was located in the home, and in just 40.6% of these homes did everyone in the household know how to use naloxone. Awareness and knowledge Overall, awareness about naloxone and its ability to reverse the effects of an opioid overdose was high, with 81.9% of respondents having heard about naloxone and 80.3% knowing that naloxone is used to reverse the effects of an opioid overdose (Supplemental File 2). However, awareness of the new over-the-counter (OTC) status of naloxone was low (31.8%). Additionally, knowledge about particular naloxone dosage forms available OTC was low with 79.3% of respondents indicating that they were unsure. Willingness-to-pay (WTP) for OTC naloxone The maximum price respondents were willing to pay for OTC naloxone ranged from $0 to $200, with a mean (SD) WTP of $27.06 (25.44) and median (IQR) of $20.00 (10.00–30.00) (Table 2). When asked about a reasonable price for pharmacies to charge for OTC naloxone, the most frequently selected price ranges were $20–24.99 (18.7%) and $5–9.99 (18.4%), with only 18.3% of respondents deeming prices over $29.99 as reasonable. The majority of respondents (30.4%) indicated they would not purchase OTC naloxone if it cost more than $50, while 14.7% reported that they would not purchase it at prices over $30. Additionally, 67.2% of participants indicated they would be more likely to purchase naloxone if it were run through prescription insurance. Participants with an annual household income ≥$50,000 had a higher average WTP (mean [SD]: $30.97 [30.49], median [IQR]: 22.50 [15.00–40.00]) compared to those with an annual household income <$50,000 (mean [SD]: $22.39 [16.36], median [IQR]: 20.00 [10.00–25.00]; p = 0.028, rrb = 0.128) (Table 3). There were no other statistically significant differences in WTP.Table 2Willingness-to-Pay for OTC Naloxone.Questions an (%) bIn your opinion, what is a reasonable amount for pharmacies to charge for OTC naloxone?Less than $526 (8.7)$5–9.9955 (18.4)$10–14.9942 (14.0)$15–19.9937 (12.4)$20–24.9956 (18.7)$25–29.9928 (9.4)$30–34.9915 (5.0)$35–39.9910 (3.3)$40–44.997 (2.3)$45–49.994 (1.3)$50 or more19 (6.4)I would NOT purchase OTC naloxone from the pharmacy if it cost more than ___.$522 (7.4)$1013 (0.3)$1519 (6.4)$2036 (12.0)$2533 (11.0)$3044 (14.7)$3510 (3.3)$4025 (8.4)$456 (2.0)$5091 (30.4)I would be more likely to purchase naloxone if it were:Run through my prescription insurance201 (67.2)Not run through my prescription insurance98 (32.8)Mean (SD)Median (IQR)What is the MAXIMUM amount you would be willing to pay for over-the-counter (OTC) naloxone at the pharmacy? ($)27.06 (25.44)20.00 (10.00–30.00)Range: 0–200.00aEach question contained an explanation that “Each box of OTC naloxone will contain two doses of nasal spray (enough to be used twice).”bFrequencies and percentages may differ due to item non-response.Table 3a-b. Differences in Intentions, Perceptions, and Willingness-to-Pay for OTC Naloxone Across (a) Chronic Pain History, Substance Use Disorder Experience, History of Prescription Opioid Use, and (b) Annual Household Income, Sex, Race/Ethnicity, and Rurality (N = 299).(a)MeasuresMean (SD)Median (IQR)Chronic Pain HistorySUD ExperiencePrescription Opioid HistoryMean (SD)Median (IQR)Effect Size rrbp-value aMean (SD)Median (IQR)Effect Size rrbp-value aMean (SD)Median (IQR)Effect Size rrbp-value aAll (N = 299)Yes (n = 88)No (n = 204)Yes (n = 132)No (n = 160)Yes (n = 102)No (n = 191)Intentions2.91 (0.94)2.86 (2.29–3.57)3.22 (1.03)3.21 (2.57–4.00)2.77 (0.87)2.71 (2.14–3.29)0.202<0.001*3.08 (0.94)3.00 (2.43–3.71)2.75 (0.92)2.71 (2.14–3.29)0.1620.006*2.82 (0.94)2.71 (2.25–3.32)2.95 (0.93)3.00 (2.43–3.57)0.0860.140General Attitudes3.67 (0.57)3.69 (3.31–4.08)3.79 (0.60)3.85 (3.38–4.25)3.63 (0.56)3.69 (3.31–4.08)0.1190.042*3.78 (0.59)3.85 (3.46–4.23)3.59 (0.54)3.62 (3.23–4.08)0.1700.004*3.70 (0.59)3.77 (3.31–4.08)3.67 (0.56)3.65 (3.31–4.08)0.0310.594Perceived Barriers2.41 (0.56)2.38 (2.13–2.75)2.38 (0.67)2.38 (1.97–2.88)2.41 (0.51)2.38 (2.13–2.75)0.0300.6122.46 (0.58)2.38 (2.13–2.88)2.35 (0.53)2.38 (2.00–2.75)0.0800.1722.42 (0.63)2.50 (2.06–2.88)2.40 (0.51)2.38 (2.13–2.75)0.0370.528Perceived Access3.97 (0.58)4.00 (3.60–4.40)4.09 (0.56)4.10 (3.70–4.60)3.93 (0.58)3.95 (3.60–4.30)0.1200.041*3.97 (0.60)4.00 (3.60–4.40)3.98 (0.56)4.00 (3.70–4.40)0.0100.8633.98 (0.60)4.00 (3.60–4.50)3.98 (0.57)4.00 (3.70–4.40)0.0170.776SN1.91 (0.86)1.89 (1.11–2.33)1.78 (0.83)1.56 (1.00–2.25)1.95 (0.86)1.89 (1.22–2.33)0.1050.0741.90 (0.85)1.78 (1.11–2.33)1.89 (0.86)1.78 (1.00–2.22)0.0130.8281.88 (0.87)1.78 (1.00–2.33)1.91 (0.85)1.78 (1.11–2.22)0.0190.745PBC3.31 (0.44)3.25 (3.04–3.58)3.38 (0.45)3.33 (3.08–3.67)3.29 (0.44)3.25 (3.00–3.58)0.0950.1073.30 (0.46)3.25 (3.08–3.58)3.32 (0.43)3.33 (3.08–3.58)0.0020.9753.34 (0.51)3.33 (3.08–3.67)3.30 (0.40)3.25 (3.08–3.50)0.0740.210Comfort3.82 (0.75)3.88 (3.42–4.42)4.01 (0.73)4.00 (3.67–4.67)3.75 (0.74)3.83 (3.33–4.33)0.1670.005*3.92 (0.75)4.00 (3.50–4.50)3.75 (0.75)3.83 (3.33–4.27)0.1110.0603.83 (0.72)3.83 (3.42–4.33)3.82 (0.77)4.00 (3.42–4.42)0.0200.730WTP ($)27.06 (25.44)20.00 (10.00–30.00)23.51 (16.10)20.00 (10.00–30.00)28.80 (28.54)22.50 (10.50–35.00)0.0210.35829.05 (29.06)25.00 (10.00–40.00)25.63 (22.22)20.00 (10.00–30.00)0.0170.28824.89 (24.95)20.00 (10.00–30.00)28.71 (25.85)25.00 (15.00–35.00)0.0910.120 (b)MeasuresAnnual Household IncomeSexMean (SD)Median (IQR)Effect Size rrbp-value aMean (SD)Median (IQR)Effect Size rrbp-value a<$50 K (n = 130)≥50 K (n = 164)Male (n = 156)Female (n = 137)Intentions2.91 (1.02)2.86 (225–3.46)2.91 (0.87)3.00 (2.29–3.57)0.0310.6012.90 (0.91)2.93 (2.29–3.43)2.91 (0.97)2.86 (2.29–3.57)0.0080.888General Attitudes3.69 (0.50)3.69 (3.31–4.12)3.67 (0.58)3.69 (3.31–4.08)0.0190.7443.65 (0.51)3.62 (3.31–4.08)3.69 (0.63)3.77 (3.31–4.23)0.0580.323Perceived Barriers2.48 (0.50)2.50 (2.25–2.88)2.36 (0.60)2.38 (2.00–2.75)0.1340.022*2.35 (0.52)2.38 (2.09–2.75)2.48 (0.61)2.50 (2.13–2.88)0.1250.034*Perceived Access4.01 (0.57)4.00 (3.60–4.50)3.95 (0.59)4.00 (3.60–4.40)0.0260.6623.99 (0.56)4.00 (3.70–4.40)3.96 (0.6)4.00 (3.60–4.40)0.0160.779SN1.86 (0.80)1.78 (1.06–2.22)1.95 (0.92)1.89 (1.00–2.33)0.0210.7161.88 (0.81)1.89 (1.11–2.22)1.95 (0.93)1.78 (1.00–2.39)0.0080.891PBC3.32 (0.41)3.33 (3.08–3.58)3.30 (0.47)3.25 (3.00–3.58)0.0280.6343.31 (0.45)3.33 (3.08–3.58)3.30 (0.44)3.25 (3.00–3.58)0.0230.695Comfort3.81 (0.71)3.83 (3.33–4.33)3.83 (0.79)3.92 (3.42–4.44)0.0290.6193.90 (0.65)4.00 (3.50–4.42)3.73 (0.85)3.75 (3.33–4.42)0.0900.124WTP ($)22.39 (16.36)20.00 (10.00–25.00)30.97 (30.49)22.50 (15.00–40.00)0.1280.028*27.16 (24.39)20.00 (5.00–30.00)27.00 (27.09)20.00 (10.00–30.00)0.0350.552 MeasuresRace/EthnicityRuralityMean (SD)Median (IQR)Effect Size rrbp-value aMean (SD)Median (IQR)Effect Size rrbp-value aWhite (n = 230)All Other Races/Ethnicities b (n = 68)Urban (n = 247)Rural (n = 49)Intentions2.87 (0.90)2.86 (2.29–3.43)3.06 (1.02)(3.00 (2.43–3.68)0.080.1622.94 (0.93)3.00 (2.29–3.57)2.81 (0.93)2.71 (2.29–3.250)0.0540.354General Attitudes3.67 (0.58)3.69 (3.31–4.08)3.67 (0.55)3.54 (3.31–4.08)0.030.6383.68 (0.57)3.69 (3.31–4.08)3.67 (0.60)3.62 (3.19–4.08)0.0110.847Perceived Barriers2.41 (0.58)2.38 (2.13–2.75)2.42 (0.48)2.50 (2.00–2.75)0.000.9532.40 (0.57)2.38 (2.13–2.75)2.44 (0.51)2.38 (2.13–2.88)0.0390.508Perceived Access3.97 (0.58)4.00 (3.60–4.40)3.97 (0.58)3.90 (3.70–4.40)0.020.7183.99 (0.57)4.00 (3.70–4.40)3.91 (0.59)4.00 (3.50–4.35)0.0460.430SN1.92 (0.87)1.89 (1.11–2.33)1.90 (0.83)2.00 (1.00–2.33)0.000.9391.91 (0.87)1.89 (1.06–2.33)1.92 (0.81)1.78 (1.33–2.33)0.0140.804PBC3.29 (0.46)3.25 (3.00–3.58)3.36 (0.40)3.33 (08–3.67)0.070.2633.32 (0.45)3.33 (3.08–3.58)3.26 (0.43)3.25 (2.96–3.54)0.0470.416Comfort3.80 (0.77)3.83 (3.33–4.40)3.90 (0.68)4.00 (3.50–4.42)0.060.3233.83 (0.74)3.92 (3.42–4.42)3.77 (0.79)3.83 (3.17–4.50)0.0410.487WTP ($)26.84 (26.40)20.00 (10.00–30.00)27.97 (22.23)25.00 (15.00–38.75)0.070.21427.57 (24.16)20.00 (15.00–35.00)25.72 (31.55)20.00 (10.00–27.50)0.0830.155Abbreviations: IQR = interquartile range. rrb = rank-biserial correlation coefficient (effect size). PBC = perceived behavioral control. SD = standard deviation. SN = subjective norms. SUD = substance use disorder. WTP = willingness-to-pay. | * Statistically significant at the alpha = 0.05 level. | a Mann-Whitney U test with rank-biserial correlation coefficient (rrb) as a measure of effect size. | b “All Other Races/Ethnicities” includes: Asian, Black or African American, Hispanic or Latino/a/x, Multiracial, Native American or Alaksa Native, Native Hawaiian or Other Pacific Islander, or Other. Table 2Willingness-to-Pay for OTC Naloxone.Questions an (%) bIn your opinion, what is a reasonable amount for pharmacies to charge for OTC naloxone?Less than $526 (8.7)$5–9.9955 (18.4)$10–14.9942 (14.0)$15–19.9937 (12.4)$20–24.9956 (18.7)$25–29.9928 (9.4)$30–34.9915 (5.0)$35–39.9910 (3.3)$40–44.997 (2.3)$45–49.994 (1.3)$50 or more19 (6.4)I would NOT purchase OTC naloxone from the pharmacy if it cost more than ___.$522 (7.4)$1013 (0.3)$1519 (6.4)$2036 (12.0)$2533 (11.0)$3044 (14.7)$3510 (3.3)$4025 (8.4)$456 (2.0)$5091 (30.4)I would be more likely to purchase naloxone if it were:Run through my prescription insurance201 (67.2)Not run through my prescription insurance98 (32.8)Mean (SD)Median (IQR)What is the MAXIMUM amount you would be willing to pay for over-the-counter (OTC) naloxone at the pharmacy? ($)27.06 (25.44)20.00 (10.00–30.00)Range: 0–200.00aEach question contained an explanation that “Each box of OTC naloxone will contain two doses of nasal spray (enough to be used twice).”bFrequencies and percentages may differ due to item non-response. Willingness-to-Pay for OTC Naloxone. Each question contained an explanation that “Each box of OTC naloxone will contain two doses of nasal spray (enough to be used twice).” Frequencies and percentages may differ due to item non-response. Table 3a-b. Differences in Intentions, Perceptions, and Willingness-to-Pay for OTC Naloxone Across (a) Chronic Pain History, Substance Use Disorder Experience, History of Prescription Opioid Use, and (b) Annual Household Income, Sex, Race/Ethnicity, and Rurality (N = 299).(a)MeasuresMean (SD)Median (IQR)Chronic Pain HistorySUD ExperiencePrescription Opioid HistoryMean (SD)Median (IQR)Effect Size rrbp-value aMean (SD)Median (IQR)Effect Size rrbp-value aMean (SD)Median (IQR)Effect Size rrbp-value aAll (N = 299)Yes (n = 88)No (n = 204)Yes (n = 132)No (n = 160)Yes (n = 102)No (n = 191)Intentions2.91 (0.94)2.86 (2.29–3.57)3.22 (1.03)3.21 (2.57–4.00)2.77 (0.87)2.71 (2.14–3.29)0.202<0.001*3.08 (0.94)3.00 (2.43–3.71)2.75 (0.92)2.71 (2.14–3.29)0.1620.006*2.82 (0.94)2.71 (2.25–3.32)2.95 (0.93)3.00 (2.43–3.57)0.0860.140General Attitudes3.67 (0.57)3.69 (3.31–4.08)3.79 (0.60)3.85 (3.38–4.25)3.63 (0.56)3.69 (3.31–4.08)0.1190.042*3.78 (0.59)3.85 (3.46–4.23)3.59 (0.54)3.62 (3.23–4.08)0.1700.004*3.70 (0.59)3.77 (3.31–4.08)3.67 (0.56)3.65 (3.31–4.08)0.0310.594Perceived Barriers2.41 (0.56)2.38 (2.13–2.75)2.38 (0.67)2.38 (1.97–2.88)2.41 (0.51)2.38 (2.13–2.75)0.0300.6122.46 (0.58)2.38 (2.13–2.88)2.35 (0.53)2.38 (2.00–2.75)0.0800.1722.42 (0.63)2.50 (2.06–2.88)2.40 (0.51)2.38 (2.13–2.75)0.0370.528Perceived Access3.97 (0.58)4.00 (3.60–4.40)4.09 (0.56)4.10 (3.70–4.60)3.93 (0.58)3.95 (3.60–4.30)0.1200.041*3.97 (0.60)4.00 (3.60–4.40)3.98 (0.56)4.00 (3.70–4.40)0.0100.8633.98 (0.60)4.00 (3.60–4.50)3.98 (0.57)4.00 (3.70–4.40)0.0170.776SN1.91 (0.86)1.89 (1.11–2.33)1.78 (0.83)1.56 (1.00–2.25)1.95 (0.86)1.89 (1.22–2.33)0.1050.0741.90 (0.85)1.78 (1.11–2.33)1.89 (0.86)1.78 (1.00–2.22)0.0130.8281.88 (0.87)1.78 (1.00–2.33)1.91 (0.85)1.78 (1.11–2.22)0.0190.745PBC3.31 (0.44)3.25 (3.04–3.58)3.38 (0.45)3.33 (3.08–3.67)3.29 (0.44)3.25 (3.00–3.58)0.0950.1073.30 (0.46)3.25 (3.08–3.58)3.32 (0.43)3.33 (3.08–3.58)0.0020.9753.34 (0.51)3.33 (3.08–3.67)3.30 (0.40)3.25 (3.08–3.50)0.0740.210Comfort3.82 (0.75)3.88 (3.42–4.42)4.01 (0.73)4.00 (3.67–4.67)3.75 (0.74)3.83 (3.33–4.33)0.1670.005*3.92 (0.75)4.00 (3.50–4.50)3.75 (0.75)3.83 (3.33–4.27)0.1110.0603.83 (0.72)3.83 (3.42–4.33)3.82 (0.77)4.00 (3.42–4.42)0.0200.730WTP ($)27.06 (25.44)20.00 (10.00–30.00)23.51 (16.10)20.00 (10.00–30.00)28.80 (28.54)22.50 (10.50–35.00)0.0210.35829.05 (29.06)25.00 (10.00–40.00)25.63 (22.22)20.00 (10.00–30.00)0.0170.28824.89 (24.95)20.00 (10.00–30.00)28.71 (25.85)25.00 (15.00–35.00)0.0910.120 (b)MeasuresAnnual Household IncomeSexMean (SD)Median (IQR)Effect Size rrbp-value aMean (SD)Median (IQR)Effect Size rrbp-value a<$50 K (n = 130)≥50 K (n = 164)Male (n = 156)Female (n = 137)Intentions2.91 (1.02)2.86 (225–3.46)2.91 (0.87)3.00 (2.29–3.57)0.0310.6012.90 (0.91)2.93 (2.29–3.43)2.91 (0.97)2.86 (2.29–3.57)0.0080.888General Attitudes3.69 (0.50)3.69 (3.31–4.12)3.67 (0.58)3.69 (3.31–4.08)0.0190.7443.65 (0.51)3.62 (3.31–4.08)3.69 (0.63)3.77 (3.31–4.23)0.0580.323Perceived Barriers2.48 (0.50)2.50 (2.25–2.88)2.36 (0.60)2.38 (2.00–2.75)0.1340.022*2.35 (0.52)2.38 (2.09–2.75)2.48 (0.61)2.50 (2.13–2.88)0.1250.034*Perceived Access4.01 (0.57)4.00 (3.60–4.50)3.95 (0.59)4.00 (3.60–4.40)0.0260.6623.99 (0.56)4.00 (3.70–4.40)3.96 (0.6)4.00 (3.60–4.40)0.0160.779SN1.86 (0.80)1.78 (1.06–2.22)1.95 (0.92)1.89 (1.00–2.33)0.0210.7161.88 (0.81)1.89 (1.11–2.22)1.95 (0.93)1.78 (1.00–2.39)0.0080.891PBC3.32 (0.41)3.33 (3.08–3.58)3.30 (0.47)3.25 (3.00–3.58)0.0280.6343.31 (0.45)3.33 (3.08–3.58)3.30 (0.44)3.25 (3.00–3.58)0.0230.695Comfort3.81 (0.71)3.83 (3.33–4.33)3.83 (0.79)3.92 (3.42–4.44)0.0290.6193.90 (0.65)4.00 (3.50–4.42)3.73 (0.85)3.75 (3.33–4.42)0.0900.124WTP ($)22.39 (16.36)20.00 (10.00–25.00)30.97 (30.49)22.50 (15.00–40.00)0.1280.028*27.16 (24.39)20.00 (5.00–30.00)27.00 (27.09)20.00 (10.00–30.00)0.0350.552 MeasuresRace/EthnicityRuralityMean (SD)Median (IQR)Effect Size rrbp-value aMean (SD)Median (IQR)Effect Size rrbp-value aWhite (n = 230)All Other Races/Ethnicities b (n = 68)Urban (n = 247)Rural (n = 49)Intentions2.87 (0.90)2.86 (2.29–3.43)3.06 (1.02)(3.00 (2.43–3.68)0.080.1622.94 (0.93)3.00 (2.29–3.57)2.81 (0.93)2.71 (2.29–3.250)0.0540.354General Attitudes3.67 (0.58)3.69 (3.31–4.08)3.67 (0.55)3.54 (3.31–4.08)0.030.6383.68 (0.57)3.69 (3.31–4.08)3.67 (0.60)3.62 (3.19–4.08)0.0110.847Perceived Barriers2.41 (0.58)2.38 (2.13–2.75)2.42 (0.48)2.50 (2.00–2.75)0.000.9532.40 (0.57)2.38 (2.13–2.75)2.44 (0.51)2.38 (2.13–2.88)0.0390.508Perceived Access3.97 (0.58)4.00 (3.60–4.40)3.97 (0.58)3.90 (3.70–4.40)0.020.7183.99 (0.57)4.00 (3.70–4.40)3.91 (0.59)4.00 (3.50–4.35)0.0460.430SN1.92 (0.87)1.89 (1.11–2.33)1.90 (0.83)2.00 (1.00–2.33)0.000.9391.91 (0.87)1.89 (1.06–2.33)1.92 (0.81)1.78 (1.33–2.33)0.0140.804PBC3.29 (0.46)3.25 (3.00–3.58)3.36 (0.40)3.33 (08–3.67)0.070.2633.32 (0.45)3.33 (3.08–3.58)3.26 (0.43)3.25 (2.96–3.54)0.0470.416Comfort3.80 (0.77)3.83 (3.33–4.40)3.90 (0.68)4.00 (3.50–4.42)0.060.3233.83 (0.74)3.92 (3.42–4.42)3.77 (0.79)3.83 (3.17–4.50)0.0410.487WTP ($)26.84 (26.40)20.00 (10.00–30.00)27.97 (22.23)25.00 (15.00–38.75)0.070.21427.57 (24.16)20.00 (15.00–35.00)25.72 (31.55)20.00 (10.00–27.50)0.0830.155Abbreviations: IQR = interquartile range. rrb = rank-biserial correlation coefficient (effect size). PBC = perceived behavioral control. SD = standard deviation. SN = subjective norms. SUD = substance use disorder. WTP = willingness-to-pay. | * Statistically significant at the alpha = 0.05 level. | a Mann-Whitney U test with rank-biserial correlation coefficient (rrb) as a measure of effect size. | b “All Other Races/Ethnicities” includes: Asian, Black or African American, Hispanic or Latino/a/x, Multiracial, Native American or Alaksa Native, Native Hawaiian or Other Pacific Islander, or Other. a-b. Differences in Intentions, Perceptions, and Willingness-to-Pay for OTC Naloxone Across (a) Chronic Pain History, Substance Use Disorder Experience, History of Prescription Opioid Use, and (b) Annual Household Income, Sex, Race/Ethnicity, and Rurality (N = 299). Abbreviations: IQR = interquartile range. rrb = rank-biserial correlation coefficient (effect size). PBC = perceived behavioral control. SD = standard deviation. SN = subjective norms. SUD = substance use disorder. WTP = willingness-to-pay. | * Statistically significant at the alpha = 0.05 level. | a Mann-Whitney U test with rank-biserial correlation coefficient (rrb) as a measure of effect size. | b “All Other Races/Ethnicities” includes: Asian, Black or African American, Hispanic or Latino/a/x, Multiracial, Native American or Alaksa Native, Native Hawaiian or Other Pacific Islander, or Other. Preferences regarding the sale of OTC naloxone in the community pharmacy setting In terms of placement and marketing of OTC naloxone in the pharmacy, respondents preferred that OTC naloxone be placed in a prominent location in the pharmacy that is easy to find (47.2% agreed or strongly agreed) rather than a more discrete area of the pharmacy (9.1%) (Fig. 1 and Supplemental File 2). Likewise, 47.8% preferred signage in the pharmacy to indicate which aisle OTC naloxone was on, and 37.7% were in support of posters or flyers in the pharmacy to advertise OTC naloxone. The majority of participants preferred to purchase OTC naloxone online from the pharmacy website or app (53.1%), followed by in-person at the pharmacy (38.4%), and lastly from the pharmacy drive-thru (33.6%). Regarding communicating with the pharmacist about OTC naloxone, most preferred to initiate a conversation about OTC naloxone with the pharmacist themselves (45.8%) rather than the pharmacist initiating the conversation (17.5%).Fig. 1Preferences Regarding OTC Naloxone Sales in Community Pharmacies (N = 299).Fig. 1 Preferences Regarding OTC Naloxone Sales in Community Pharmacies (N = 299). Perceived ability to access OTC naloxone in a local community pharmacy The perceived ability to access OTC naloxone in a local community pharmacy was generally high (mean [SD] scale score: 3.97 [0.58]) (Cronbach's α = 0.854) (Supplemental File 2). For example, a majority of respondents agreed or strongly agreed that they trust their local pharmacy to help them understand how to properly use OTC naloxone (87.6%), that their local pharmacy keeps convenient hours (73.4%), pharmacy signage is easy to read (73.1%), and that pharmacy staff would be courteous enough to help them locate OTC naloxone if they could not find it on their own (85.5%). The lowest rated item was the perception that the pharmacy would be able to quickly get more OTC naloxone in stock if they ran out (44.8%). Furthermore, perceived pharmacy access to OTC naloxone was higher among those with a history of chronic pain (4.09 [0.56]) compared to those without chronic pain (3.93 [0.58]; p = 0.041, rrb = 0.120) (Table 3). There were no other statistically significant differences in perceived pharmacy access. Perceived barriers to obtaining OTC naloxone Mean (SD) perceived barriers to obtaining OTC naloxone were low overall (scale score: 2.41 [0.56]) (Cronbach's α = 0.668) (Supplemental File 2). In particular, difficulty understanding the instructions for how to use OTC naloxone (2.3% agreed or strongly agreed), difficulty finding pharmacies that stocked OTC naloxone (4.3%), transportation to the pharmacy to purchase OTC naloxone (6.1%), and insufficient amounts of OTC naloxone stocked in pharmacies (6.4%) were infrequently perceived as barriers. In comparison, high cost of OTC naloxone (17.9%), lack of insurance coverage (23.6%), and budgetary constraints (40.8%) were more often perceived as barriers. Notably, the most frequently endorsed barrier was concern regarding the potential for OTC naloxone to be stolen off pharmacy shelves (49.1%), representing a pharmacy-level barrier that respondents believed could affect product availability. Furthermore, mean (SD) perceived barriers to obtaining OTC naloxone were higher among participants with an annual household income <$50,000 (2.48 [0.50]) compared to ≥$50,000 (2.36 [0.60]; p = 0.022, rrb = 0.134), and among females (2.48 [0.61]) versus males (2.35 [0.52]; p = 0.034, rrb = 0.125) (Table 3). There were no other statistically significant differences in perceived barriers. Comfort utilizing OTC naloxone Comfort utilizing OTC naloxone was relatively high (mean [SD] scale score: 3.82 [0.75]) (Cronbach's α = 0.887) (Supplemental File 2). Specifically, 53.7% agreed or strongly agreed that they felt capable of correctly identifying the signs and symptoms of an opioid overdose, 85.5% felt comfortable storing OTC naloxone in their home, and 58.1% felt comfortable administering OTC naloxone to a friend or family member. Most respondents stated that they would feel more comfortable administering OTC naloxone after watching an instructional video (82.1%), followed by speaking with their physician (72.0%) or consulting with their pharmacist (69.6%). Participants felt most comfortable purchasing OTC naloxone from a traditional free-standing community pharmacy (82.1%), followed by a big-box store (78.4%), online marketplace (75.7%), grocery store (74.3%), vending machine (55.4%), or gas station/convenience store (51.4%). Additionally, mean (SD) comfort utilizing OTC naloxone was higher among individuals with a history of chronic pain (4.01 [0.73]) compared to those without a history of chronic pain (3.75 [0.74]; p = 0.005, rrb = 0.167) (Table 3). General attitudes about OTC naloxone In general, mean (SD) attitudes toward OTC naloxone were positive (scale score: 3.67 [0.57]) (Cronbach's α = 0.822), with 85.2% of respondents agreeing or strongly agreeing that OTC naloxone is “beneficial” and 80.4% that it is “good” (Supplemental File 2). When asked about purchasing prescription-only or OTC naloxone, more respondents indicated that they would purchase OTC versus prescription naloxone if needed (85.5% vs 69.3%), and 45.1% stated that they preferred OTC over prescription-only naloxone. Interestingly, there were mixed responses in regards to purchasing OTC naloxone based on perceived risk for the individual respondent versus friends and family members. Specifically, 48.2%% agreed or strongly agreed that they would never need to purchase OTC naloxone because they would never be at risk for opioid overdose, while fewer (28.9%) indicated that they would never need to purchase OTC naloxone because their friends and family members would never be at risk. Additionally, individuals with chronic pain had significantly more positive mean (SD) general attitudes (3.79 [0.60]) toward obtaining OTC naloxone compared to those without chronic pain (3.63 [0.56]; p = 0.042, rrb = 0.119). The same was true for those with SUD exposure (3.78 [0.59]) compared to those without (3.59 [0.54]; p = 0.004, rrb = 0.170). There were no other statistically significant differences in attitudes (Table 3). Subjective norms surrounding OTC naloxone Perceived negative social pressure surrounding OTC naloxone was low (mean [SD] scale score: 1.91 [0.86]) (Cronbach's α = 0.938) (Supplemental File 2). In particular, embarrassment due to being seen purchasing OTC naloxone by co-workers (14.5% agreed or strongly agreed), pharmacy staff (14.2%), friends (12.1%), or family (10.5) was low. Furthermore, only 8.1% believed that their pharmacist and 7.5% that their doctor would look down on them for purchasing OTC naloxone, and 8.4% stated that their community would not be open to OTC naloxone. There were no statistically significant differences in subjective norms across chronic pain, SUD, opioid use history, or other sociodemographic characteristics (Table 3). Perceived behavioral control over obtaining OTC naloxone Overall, perceived behavioral control over obtaining OTC naloxone was positive (mean [SD] scale score: 3.31 [0.44]) (Cronbach's α = 0.678), although item-level responses were mixed (Supplemental File 2). In particular, items related to individual agency, home-life, and the workplace were positively rated, with 75.8% agreeing or strongly agreeing that they were confident in their ability to obtain OTC naloxone if needed. Further, 89.2% stated that they would be able to make the decision as to whether OTC naloxone was kept in their home, while 59.9% believed that they would have control over carrying OTC naloxone at work. On the other hand, items related to healthcare organizations or external policies were negatively rated. For example, 80.1% stated that they had no influence over whether OTC naloxone was available in their pharmacy, and 91.2% that they had no control over the price of OTC naloxone. There were no statistically significant differences in perceived behavioral control across chronic pain, SUD, opioid use history, or other sociodemographic characteristics (Table 3). Intention to obtain OTC naloxone Overall, mean (SD) intention to obtain OTC naloxone was low (scale score: 2.91 [0.94]) (Cronbach's α = 0.883), with 72.6% of participants disagreeing or strongly disagreeing with the statement “I plan to obtain OTC naloxone” (Supplemental File 2). However, 47% of respondents agreed or strongly agreed they would obtain OTC naloxone if prescribed an opioid medication for themselves, and 53.5% would obtain OTC naloxone if they knew a friend or family member was prescribed an opioid medication. A larger proportion of respondents (74.6%) stated that they would obtain OTC naloxone if a friend or family member was using illegal or illicit obtained opioids. Furthermore, individuals with a history of chronic pain had higher mean (SD) intentions (3.22 [1.03]) toward obtaining OTC naloxone compared to those without chronic pain (2.77 [0.87]; p < 0.001, rrb = 0.202) (Table 3). Similarly, individuals with SUD exposure also had significantly higher intentions (3.08 [0.94]) to obtain OTC naloxone compared to those without exposure to SUD (2.75 [0.82]; p = 0.006, rrb = 0.162). There were no other statistically significant differences in intention. Additionally, after controlling for covariates in multiple linear regression analyses, general attitudes (β = 0.792, 95%CI = 0.604, 0.979; p < 0.001) and subjective norms (β = 0.144, 95%CI = 0.016, 0.271; p = 0.027) were positive predictors of intention to obtain OTC naloxone (Table 4, Model 2). Although comfort utilizing OTC naloxone was a statistically significant predictor of purchase intentions in the unadjusted regression model (Table 4, Model 1), it was no longer a statistically significant predictor after adjusting for covariates.Table 4Predictors of Intention to Purchase OTC Naloxone.a Model 1: R2 = 0.339, F(df) = 24.719(6), p < 0.001b Model 2: R2 = 0.435, F(df) = 13.576, p < 0.001Predictorsβ95% CIp-valueβ95% CIp-valueGeneral Attitudes0.8400.655, 1.025<0.001⁎0.7920.604, 0.979<0.001⁎Perceived Barriers0.103−0.76, 0.2810.2580.055−0.128, 0.2370.556Perceived Access0.017−0.168, 0.2020.8530.078−0.105, 0.2610.403SN0.1930.064, 0.3220.004⁎0.1440.016, 0.2710.027⁎PBC0.152−0.090, 0.3940.2170.181−0.055, 0.4180.133Comfort0.2200.059, 0.3800.007⁎0.105−0.058, 0.2680.207⁎Statistically significant at the alpha = 0.05 level.aLinear regression. Dependent variable = intention mean scale score. Predictors = general attitudes, perceived barriers, perceived ability to access OTC naloxone, subjective norms, perceived behavioral control, and comfort utilizing OTC naloxone mean scale scores.bLinear regression. Dependent variable = intention mean scale score. Predictors = general attitudes, perceived barriers, perceived ability to access OTC naloxone, subjective norms, perceived behavioral control, and comfort utilizing OTC naloxone mean scale scores. Controlling for covariates: naloxone purchase history (Yes/No), sex, age, race/ethnicity, education level, annual household income, history of chronic pain (Yes/No), experience with opioid or substance use disorder (Yes/No), history of prescription opioid use (Yes/No). Model assumptions were met including no autocorrelation, multicollinearity, influential outliers, or heteroskedasticity (Durbin-Watson = 2.023, VIF < 5, Cook's Distance <1, White Test for Heteroskedasticity p = 0.105, respectively). Multivariate normality was indicated by the histogram and normal P—P plot of standardized residuals, and collective linearity was inferred from the scatterplot of standardized residuals versus predicted values. Table 4Predictors of Intention to Purchase OTC Naloxone.a Model 1: R2 = 0.339, F(df) = 24.719(6), p < 0.001b Model 2: R2 = 0.435, F(df) = 13.576, p < 0.001Predictorsβ95% CIp-valueβ95% CIp-valueGeneral Attitudes0.8400.655, 1.025<0.001⁎0.7920.604, 0.979<0.001⁎Perceived Barriers0.103−0.76, 0.2810.2580.055−0.128, 0.2370.556Perceived Access0.017−0.168, 0.2020.8530.078−0.105, 0.2610.403SN0.1930.064, 0.3220.004⁎0.1440.016, 0.2710.027⁎PBC0.152−0.090, 0.3940.2170.181−0.055, 0.4180.133Comfort0.2200.059, 0.3800.007⁎0.105−0.058, 0.2680.207⁎Statistically significant at the alpha = 0.05 level.aLinear regression. Dependent variable = intention mean scale score. Predictors = general attitudes, perceived barriers, perceived ability to access OTC naloxone, subjective norms, perceived behavioral control, and comfort utilizing OTC naloxone mean scale scores.bLinear regression. Dependent variable = intention mean scale score. Predictors = general attitudes, perceived barriers, perceived ability to access OTC naloxone, subjective norms, perceived behavioral control, and comfort utilizing OTC naloxone mean scale scores. Controlling for covariates: naloxone purchase history (Yes/No), sex, age, race/ethnicity, education level, annual household income, history of chronic pain (Yes/No), experience with opioid or substance use disorder (Yes/No), history of prescription opioid use (Yes/No). Model assumptions were met including no autocorrelation, multicollinearity, influential outliers, or heteroskedasticity (Durbin-Watson = 2.023, VIF < 5, Cook's Distance <1, White Test for Heteroskedasticity p = 0.105, respectively). Multivariate normality was indicated by the histogram and normal P—P plot of standardized residuals, and collective linearity was inferred from the scatterplot of standardized residuals versus predicted values. Predictors of Intention to Purchase OTC Naloxone. Statistically significant at the alpha = 0.05 level. Linear regression. Dependent variable = intention mean scale score. Predictors = general attitudes, perceived barriers, perceived ability to access OTC naloxone, subjective norms, perceived behavioral control, and comfort utilizing OTC naloxone mean scale scores. Linear regression. Dependent variable = intention mean scale score. Predictors = general attitudes, perceived barriers, perceived ability to access OTC naloxone, subjective norms, perceived behavioral control, and comfort utilizing OTC naloxone mean scale scores. Controlling for covariates: naloxone purchase history (Yes/No), sex, age, race/ethnicity, education level, annual household income, history of chronic pain (Yes/No), experience with opioid or substance use disorder (Yes/No), history of prescription opioid use (Yes/No). Model assumptions were met including no autocorrelation, multicollinearity, influential outliers, or heteroskedasticity (Durbin-Watson = 2.023, VIF < 5, Cook's Distance <1, White Test for Heteroskedasticity p = 0.105, respectively). Multivariate normality was indicated by the histogram and normal P—P plot of standardized residuals, and collective linearity was inferred from the scatterplot of standardized residuals versus predicted values. Discussion This study explored the U.S. general public's knowledge, perceptions, and willingness-to-pay regarding OTC nasal spray naloxone, and differences across sociodemographic characteristics. Statistically significant differences in perceptions, intentions, and WTP were found across chronic pain history, SUD experience, annual household income, and sex, although all effect size estimates (rrb) were low. In particular, chronic pain history emerged as a key factor, with higher perceived pharmacy access, comfort, general attitudes, and OTC naloxone purchase intentions among those reporting a history of chronic pain. Likewise, those with exposure to SUD reported more positive attitudes and higher purchase intentions. This may potentially be explained by greater familiarity with local pharmacies and an increased knowledge of overdose risks among those with chronic pain and exposure to SUD; indeed, previous research found that individuals exposed to opioid misuse reported greater readiness to respond to an overdose.17 Interestingly, females perceived more barriers to OTC naloxone access compared to males, which aligns with previous research that found females reported greater barriers to accessing healthcare in general.35 Furthermore, WTP for OTC naloxone did not differ across any sociodemographic characteristics other than annual household income, with lower average WTP among those reporting an annual household income of less than $50,000. A more nuanced discussion of OTC naloxone knowledge, WTP, perceptions, and intentions follows. The findings from this study indicate a relatively high level of awareness regarding naloxone among participants, with the majority reporting prior knowledge of naloxone and recognizing its role in reversing opioid overdoses. However, knowledge about the recent U.S. FDA approval of OTC naloxone was considerably lower, with less than one-third of participants being aware of this regulatory change. These findings align with previous studies that highlight general public awareness of naloxone but also demonstrate knowledge gaps regarding its accessibility.36 Additionally, knowledge about OTC naloxone dosage forms was also low. Although detailed knowledge of specific naloxone dosage forms may not be critical for all individuals of the lay public, uncertainty regarding how OTC naloxone is administered may affect confidence in use and perceived preparedness to respond to an overdose.37, 38 In this context, low awareness of available OTC formulations may reflect broader gaps in understanding surrounding naloxone access and use, which could serve as a barrier to purchase or utilization among lay responders.39, 40 In addition, while prior research has reported that community-based naloxone education programs have successfully increased awareness and reduced stigma,41 the current survey study indicates misconceptions remain about naloxone availability, administration, and purpose. As stated by Previti and colleagues, “more widespread publicization of the use and accessibility of naloxone will increase community awareness” of this medication.39 From a public health perspective, improving knowledge about naloxone, particularly its OTC availability, is essential for maximizing its life-saving potential. Public health initiatives, including pharmacist-led education, targeted social media campaigns, and healthcare provider discussions, could help bridge this knowledge gap. Increasing knowledge may also play a role in improving naloxone uptake and utilization, particularly among individuals at higher risk for opioid overdose or those in positions to intervene in overdose situations. Future research should explore effective educational strategies and their impact on naloxone awareness and accessibility. Further, there is a threshold as to how much the general public is willing to pay for OTC naloxone. While the mean WTP was approximately $27 USD, the median was lower at $20, indicating a right-skewed distribution influenced by a small number of higher responses. Consistent with this, most respondents felt a reasonable amount for pharmacies to charge for OTC naloxone would be a price less than $25. This shows that most people would not be willing to purchase OTC naloxone at current retail prices, as the average out-of-pocket cost of prescription naloxone nasal spray for those without insurance in 2022 was approximately $70,15 with a suggested retail price for OTC naloxone of $45.99 in 2023.21 Indeed, budgetary constraints were a major barrier to OTC naloxone access reported in the current study. Additionally, the majority of respondents indicated they would be more likely to purchase naloxone if it were run through their prescription insurance, a potential barrier for many in the current study due to lack of coverage, and a major barrier to accessibility of OTC naloxone identified in previous studies.13 Thus, affordability of OTC naloxone is a concern and strategies to increase its accessibility, such as point-of-sale discounts in pharmacies,42 are crucial. Many of the preferences that respondents expressed regarding OTC naloxone sales in community pharmacies would enhance the product's accessibility, including placement in a prominent location, aisle signage, posters and flyers. However, Loera and colleagues found that placement of OTC naloxone in pharmacies is variable, with some placing the product in less visible areas of the pharmacy such as behind the pharmacy counter, or out on the shelf but with theft-deterrent measures such as redeemable cards.19 Aligning in-store product placement with consumer preferences would increase product purchases. A robust online marketplace associated with the pharmacy, including the ability to order via an app for same-day delivery, would further enhance OTC naloxone purchases, given online ordering was the preferred method of pharmacy-based purchase for the majority of participants, and 75.7% felt comfortable ordering from an online marketplace in general. In light of the rise in popularity of online marketplaces post-COVID-19 pandemic, this preference is no surprise.43 However, in-store stocking of OTC naloxone remains critical, as 82.1% of individuals felt comfortable purchasing it from a free-standing community pharmacy, over one-third of participants preferred to purchase it in-person at a pharmacy rather than through the pharmacy's website or drive-thru, and the highest-rated concern regarding community pharmacy-based access was the ability of the pharmacy to quickly replenish the stock of OTC naloxone if it ran out. Furthermore, in terms of communication preferences, most individuals preferred to initiate a conversation about OTC naloxone with the pharmacist themselves, rather than the pharmacist initiating the conversation. This aligns with communication preferences seen in previous studies regarding prescription naloxone, in which a general advertisement (poster or flyer) for naloxone was preferred over a universal or targeted offer of naloxone from the pharmacist.17 Future research may investigate differences in communication style preferences between OTC and prescription naloxone product recommendations. Attitudes toward OTC naloxone were positive among the US general public overall, echoing previous findings regarding positive naloxone-related beliefs prior to FDA approval of OTC naloxone.17 Indeed, in the current study, more respondents indicated a preference for purchasing OTC naloxone compared to prescription-only naloxone. However, it is interesting to note that attitudes varied based on the intended recipient of naloxone, with perceived need for OTC naloxone rated more highly when intended for use by friends or family members compared to the purchaser themselves. This aligns with previous work by Bagley and colleagues that found 91% of opioid and naloxone education attendees were parents of individuals with OUD.44 Thus, appealing to individuals' desire to protect loved ones may represent an influential factor to leverage in future interventions to enhance OTC naloxone utilization. In addition to positive attitudes in general, there were low perceptions of negative social pressure (subjective norms) in the current study, including infrequent reports of fear of purchasing OTC naloxone due to judgement from family/friends, co-workers, or healthcare professionals. Similarly, participants' confidence in their ability to obtain OTC naloxone (perceived behavioral control) was high, particularly related to individual agency, home-life, and the workplace. Taken together, this suggests that the OTC status of naloxone nasal spray may mitigate high levels of stigma associated with prescription-only naloxone seen in previous studies.37, 38 This may be due to a normalizing effect of OTC naloxone being marketed as a main-stream product on pharmacy shelves and via online retailers along with other common OTC medications, or the ability to make a more anonymous purchase online.40 Of note, while the OTC status of naloxone and its presence alongside other non-prescription products may help reduce stigma and normalize its use, this does not necessarily equate to high levels of public awareness or understanding.40 In the current study, awareness of OTC naloxone availability remained low, suggesting that targeted education and strategic promotion within pharmacies may be necessary to complement the normalizing effects of OTC availability.40, 41 Thus, further research is needed to explore shifts in attitudes, subjective norms, and perceived behavioral control before and after FDA approval of OTC naloxone. Furthermore, although intentions to obtain OTC naloxone were low overall, purchase intentions were higher in cases where friends or family were prescribed an opioid medication or using an illicit opioid. This echoes the findings discussed above regarding more positive attitudes and low negative social pressure surrounding friends/family and OTC naloxone utilization. Additionally, general attitudes and negative social pressure (subjective norms) positively predicted intentions to obtain OTC naloxone. This is an interesting finding concerning subjective norms, potentially suggesting that increased social pressure may have an atypical motivating effect on OTC naloxone purchase intentions. Future research may wish to investigate motivation factors driving OTC naloxone acquisition in individuals with and without a supportive social environment, exploring more nuanced external social pressures (e.g., peer pressure, family pressure)45 than were included in the current study. Limitations There are several limitations to this study, including the cross-sectional design, which limits the causal conclusions that can be drawn. Future studies may wish to explore naloxone perceptions and utilization before and after naloxone nasal spray obtained OTC status. Further, social desirability bias and selection bias cannot be discounted, although the anonymous nature of the survey may have mitigated some of these potential biases. Additionally, the majority of respondents were White and resided in urban areas; future studies may wish to purposively recruit a more diverse sample to further explore potential disparities in OTC naloxone access. Similarly, data were collected using MTurk and restricted to participants with “Master” status to enhance response quality; however, this approach may favor individuals with substantial prior experience completing online surveys. As a result, the participants may be representative of a national online sample versus the broader U.S. population, which may explain the predominance of urban respondents. Future studies may wish to use mixed-mode sampling to improve generalizability. Conclusion Overall, awareness and knowledge regarding OTC naloxone were low among the U.S. general public, with a mean WTP of approximately $27, which is below current average retail prices. Participants felt more comfortable purchasing OTC naloxone from a traditional free-standing community pharmacy compared to any other marketplace, although online pharmacy purchases were preferred over in-person or drive-thru. Perceptions, intentions, and WTP differed across chronic pain history, SUD experience, annual household income, and sex. Future research may wish to further investigate these disparities. Furthermore, general attitudes and subjective norms were positive predictors of intention to obtain OTC naloxone. These key factors may be leveraged in future educational programs, interventions, and policies to enhance utilization of and access to OTC naloxone in community pharmacies and other marketplaces. CRediT authorship contribution statement Autumn Randles: Visualization, Validation, Data curation, Writing – original draft. Emma Tidmore: Visualization, Validation, Data curation, Writing – original draft. Kathlyn Smith: Visualization, Validation, Data curation, Writing – original draft. Melissa Sanders: Visualization, Validation, Data curation, Writing – original draft. Asia White: Visualization, Validation, Data curation, Writing – original draft. Allison Given: Visualization, Validation, Methodology, Investigation, Data curation, Conceptualization, Writing – review & editing. Amelia Unione Contreras: Visualization, Validation, Methodology, Investigation, Data curation, Conceptualization, Writing – review & editing. Alex Rodriguez-Ramos: Visualization, Validation, Methodology, Investigation, Data curation, Conceptualization, Writing – review & editing. Cameron Carter: Visualization, Validation, Methodology, Investigation, Data curation, Conceptualization, Writing – review & editing. Anne Taylor: Visualization, Validation, Supervision, Data curation, Writing – original draft. Nicholas McCormick: Visualization, Validation, Supervision, Data curation, Writing – original draft. Brandy Davis: Visualization, Validation, Data curation, Writing – review & editing. Lindsey Hohmann: Visualization, Validation, Supervision, Software, Resources, Project administration, Methodology, Investigation, Funding acquisition, Formal analysis, Data curation, Conceptualization, Writing – original draft. Consent to publish Not applicable. Ethics approval and consent to participate All study procedures received ethical approval via the primary author's Institutional Review Board (Protocol #23–412 EX 2308), and all respondents provided consent to participate. Funding This study was funded by internal funds from the Auburn University Harrison College of Pharmacy. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Declaration of competing interest The authors have no conflicts of interest to disclose.